Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

PHASE2TerminatedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

May 6, 2009

Primary Completion Date

October 7, 2018

Study Completion Date

October 7, 2018

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Lenalidomide

Starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months

DRUG

Fludarabine

30 mg/m\^2 intravenously daily on days -5, -4, -3.

DRUG

Rituximab

375 mg/m2 intravenously on day -13, and 1000 mg/m\^2 on days -6, +1 and +8.

DRUG

Thymoglobulin

1.0 mg/kg intravenously over 4 hours (day -2 and -1).

PROCEDURE

Stem Cell Transplantation

On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes.

DRUG

Bendamustine

130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).

DRUG

Allopurinol

300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER